Current advances in the elimination of hepatitis B in China by 2030

With its 78 million chronic carriers, hepatitis B virus (HBV) infection is still one of the leading public health challenges in China. Over the last two decades, China has made great progress on the prevention of HBV transmission through national vaccination programs. Zero transmission from mother t...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers of medicine 2017-12, Vol.11 (4), p.490-501
Main Authors: Zhang, Shuye, Wang, Fusheng, Zhang, Zheng
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
biomarker
CHB
China - epidemiology
coinfection
functional cure
HBV
Hepatitis
Hepatitis B
Hepatitis B - epidemiology
Hepatitis B - therapy
Hepatitis B - virology
Hepatitis B virus - drug effects
Hepatitis B virus - physiology
HIV Infections - epidemiology
HIV Infections - prevention & control
Humans
Interferon
Medicine
Medicine & Public Health
Public Health - methods
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With its 78 million chronic carriers, hepatitis B virus (HBV) infection is still one of the leading public health challenges in China. Over the last two decades, China has made great progress on the prevention of HBV transmission through national vaccination programs. Zero transmission from mother to infant has been proposed as the current goal. Available anti-HBV therapy is efficacious in suppressing HBV replication; however, it fails to completely cure patients with chronic hepatitis B and even requires lifelong treatment. To reduce the costs and improve the efficacy, several trials have been recently conducted in China to optimize the current anti-HBV managements. Novel biomarkers were identified to predict treatment outcomes, and new promising treatment strategies were developed. Reports also indicate that coinfections of HBV with other hepatotropic viruses and human immunodeficiency virus are common in China and cause severe liver diseases, which should be recognized early and treated properly. Work is still needed to eliminate hepatitis B in China by 2030.
ISSN:2095-0217
2095-0225
DOI:10.1007/s11684-017-0598-4